Mimedx Group vs Nexgel
Mimedx Group is the larger business, with $419m of revenue in fiscal 2025 against $11.4m for Nexgel (36.7 times as much). Nexgel grew faster (31.5% against 20.0%). Mimedx Group kept more of each dollar of sales as profit: a net margin of 11.6% against -26.3%.
| Latest fiscal year | Mimedx GroupMDXG, 2025 | NexgelNXGL, 2025 |
|---|---|---|
| Revenue | $419m | $11.4m |
| Revenue growth | 20.0% | 31.5% |
| Net income | $48.6m | −$3.0m |
| Operating margin | — | -29.3% |
| Net margin | 11.6% | -26.3% |
| Return on equity | 21.6% | -58.7% |
| Free cash flow | $74.0m | −$1.4m |
| Cash | $166m | — |
| Total debt | $18.0m | $687,000 |
| Debt to equity | — | 15.4% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $0 | — |
| Employees | 808 | 19 |
| Market value | $462m | $39.8m |
| Price vs our value range | Below our value range | — |
| Moat score | 59 (Moderate) | 8 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 12 sales |